Ikonisys completes acquisition of Hospitex through share issue

Ikonisys SA, specialized in automated oncology diagnostics, has completed the acquisition of Hospitex International Srl. This transaction was concluded by the issuance of 2 million new shares in favor of ETH Scientific Srl, former owner of the Italian company. The acquisition, announced in November 2023, was made for an amount of €4.5 million at a price of €2.25 per share.

This acquisition marks the introduction of Ikonisys’ new identity, renamed ALIKO SCIENTIFIC, with the ambition of becoming a global leader in next-generation oncology diagnostics. Despite the capital increase, Ikonisys is not adding immediate liquidity and is thus offsetting debt.

The issuance of shares, approved by the Board of Directors, is based on the 17th resolution of the General Meeting of September 2024. This operation slightly impacts the dilution of shareholders, bringing the total number of shares to 13,261,485.